Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine against Sudan ebolavirus, with healthy volunteers receiving the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Uganda. There are currently no approved vaccines for this strain of ebolavirus, which saw an outbreak end just last year.
Now Accepting Nominations for 2025 Gold Medal and Rising Star Award
We invite you to nominate candidates whose contributions to immunology and public health deserve to be recognized by our highest scientific honor. Learn more.
Kelly Warfield joins Sabin as new President of R&D
A seasoned executive and scientist, Warfield comes on board as we drive our current candidate vaccines for Marburg and Sudan ebolavirus toward licensure and look to expand our vaccine pipeline.
Confronting Deadly Diseases
Vaccines are our best defense against disease. Yet, we still have lethal diseases that need a vaccine solution urgently. Sabin’s R&D team is tackling two such threats: Sudan ebolavirus and Marburg virus disease. There are no approved vaccines for either of these viruses which have left behind a trail of outbreaks, ending many lives and livelihoods in Africa. Sabin’s vaccines are in Phase 2 clinical trials in Uganda and Kenya.
Making a Case for Vaccines
We make vaccines more accessible, enable innovation and expand immunization across the globe.